Scientists Develop Early Alzheimer’s Detection Test – Years Before Symptoms Appear
A new biomarker test can detect early-stage tau protein clumping up to a decade before it appears on brain scans, improving ...
New test could detect Alzheimer’s sign a decade before it shows up on brain scans
Alzheimer’s disease — which affects an estimated 7 million Americans — is notoriously difficult to detect, especially in its ...
ScienceAlert on MSN2d
A Man Fated to Get Alzheimer's Avoided It For Decades. But How?
In an exceptionally rare case, a patient with a high genetic risk of developing Alzheimer's appears to have avoided his ...
Hosted on MSN1d
Monoclonal Antibodies for Early Alzheimer's Disease
Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...
Daijiworld5d
Can gum infections lead to Alzheimer’s? New study unveils shocking link
A growing body of research suggests that infections, including those caused by common bacteria in gum disease, could ...
ScienceAlert on MSN6d
The Cause of Alzheimer's Might Be Coming From Inside Your Mouth
In recent years, a growing number of scientific studies have backed an alarming hypothesis: Alzheimer's disease isn't just a ...
News Medical on MSN6d
Blood test for Alzheimer’s could replace costly and invasive spinal taps
Researchers indicate that the Lumipulse p-tau217 assay may reduce over 50% of lumbar punctures performed for diagnosing ...
manilatimes1d
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease
PMN310 is a humanized monoclonal antibody (mAb) designed and developed to selectively target only soluble amyloid-beta ...
Alzheimer’S Therapeutics Market Poised For Growth: Projected To Surpass USD 10,433.9 Million By 2035 | Future Market Insights, Inc.
The growth of the Alzheimer's Disease Therapeutics Market is directly influenced by the increasing prevalence of Alzheimer's disease globally. The hi ...
Could Alzheimer’s begin in your mouth? Research uncovers a potential bacterial trigger
Recent research links Alzheimer's disease to bacterial gum infections, specifically the pathogen Porphyromonas gingivalis.
Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit
Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today announced that Mary Hamby, PhD will ...